<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718116</url>
  </required_header>
  <id_info>
    <org_study_id>668/24.02.2020</org_study_id>
    <nct_id>NCT04718116</nct_id>
  </id_info>
  <brief_title>Tapentadol Versus Tramadol Analgesia Post Cardiac Surgery</brief_title>
  <acronym>vasso-annie</acronym>
  <official_title>Management of Postsurgical Pain After Cardiac Operations: Comparison of Tapentadol and Tramadol Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aretaieion University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aretaieion University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized one-blinded study will be to evaluate the efficacy and&#xD;
      tolerability of two different oral doses of tapentadol and compare it to tramadol (an opioid&#xD;
      commonly used to treat post-surgical pain) in cardiac surgery patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Management of post-surgical pain is a daily challenge for every anaesthetist. Undertreated&#xD;
      post-surgical pain can result in cardiovascular, pulmonary and gastrointestinal&#xD;
      complications, as well as chronic pain and negative psychological effects. A negative impact&#xD;
      may be seen on immune function, coagulation and wound healing. Opioids have been the&#xD;
      cornerstone in the treatment of pain after cardiac surgery. However, opioids have a number of&#xD;
      adverse effects such as respiratory depression, gastrointestinal alterations, dizziness,&#xD;
      delirium, addiction.&#xD;
&#xD;
      Tapentadol is a new synthetic opioid with dual mechanism of action. It acts as a mu-receptor&#xD;
      agonist, as well as norepinephrine reuptake inhibitor. It is used to treat moderate to severe&#xD;
      pain and is associated with fewer adverse effects compared to other opioids.&#xD;
&#xD;
      The aim of this randomized one-blinded study will be to evaluate the efficacy and&#xD;
      tolerability of two different oral doses of tapentadol and compare it to tramadol (an opioid&#xD;
      commonly used to treat post-surgical pain).&#xD;
&#xD;
      Patients undergoing cardiac surgery and being discharged from ICU to ward within 30 hours of&#xD;
      surgery, will be divided into 3 groups. Group A will receive tapentadol 50mg p.o 3 times&#xD;
      daily for two days, group B will receive tapentadol 75 mg p.o 3 times daily for two days and&#xD;
      group C will receive tramadol 100 mg p.o 3 times daily for two days. Pain level will be&#xD;
      assessed with Numeric Rating Scale (NRS), before drug administration and two hours after drug&#xD;
      administration. Overall patient satisfaction will be assessed with Likert scale. Brief Pain&#xD;
      Inventory( short form) and DN4 questionnaire will be used to detect chronic pain and&#xD;
      neuropathic pain respectively, 3 and 6 months after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in pain score at rest</measure>
    <time_frame>2 hours after analgesia administration</time_frame>
    <description>pain score will be assessed by the use of Numeric Rating Scale (NRS) 2 hours after analgesia administration, ranging from 0 to 10, where 0 means &quot;no pain&quot; and 10 means &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change from baseline in pain score during coughing</measure>
    <time_frame>2 hours after analgesia administration</time_frame>
    <description>pain score will be assessed by the use of Numeric Rating Scale (NRS) 2 hours after analgesia administration, ranging from 0 to 10, where 0 means &quot;no pain&quot; and 10 means &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>side effects</measure>
    <time_frame>2 hours after analgesia administration</time_frame>
    <description>side effects resulting from analgesic administration, yes or no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of chronic pain 3 months after surgery</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>occurrence of chronic pain at the site of the operation 3 months after surgery, with the use of the Brief Pain Inventory Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of chronic pain 6 months after surgery</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>occurrence of chronic pain at the site of the operation 6 months after surgery, with the use of the Brief Pain Inventory Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of neuropathic pain 3 months after surgery</measure>
    <time_frame>3 months after surgery</time_frame>
    <description>occurrence of neuropathic pain 3 months after surgery, with the use of the Douleur Neuropathique (DN4) Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence of neuropathic pain 6 months after surgery</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>occurrence of neuropathic pain 6 months after surgery, with the use of the Douleur Neuropathique (DN4) Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hospitalization time</measure>
    <time_frame>postoperatively, an average period of 10 days</time_frame>
    <description>duration of hospital stay after surgery in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>satisfaction from postoperative analgesia</measure>
    <time_frame>72 hours postoperatively</time_frame>
    <description>satisfaction from postoperative analgesia on a six-point Likert scale with 1 marked as minimal satisfaction and 6 as maximal satisfaction</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Surgery</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Pain, Acute</condition>
  <condition>Pain, Chronic</condition>
  <condition>Pain, Procedural</condition>
  <condition>Pain, Neuropathic</condition>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>tapentadol 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tapentadol 50mg p.o 3 times daily for two days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tapentadol 75 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tapentadol 75 mg p.o 3 times daily for two days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tramadol 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tramadol 100 mg p.o 3 times daily for two days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group tapentadol 50 mg</intervention_name>
    <description>patients in group A will receive tapentadol 50 mg p.o 3 times daily for two days</description>
    <arm_group_label>tapentadol 50 mg</arm_group_label>
    <other_name>group A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group tapentadol 75 mg</intervention_name>
    <description>patients in group B will receive tapentadol 75 mg p.o 3 times daily for two days</description>
    <arm_group_label>tapentadol 75 mg</arm_group_label>
    <other_name>group B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group tramadol 100 mg</intervention_name>
    <description>patients in group C will receive tramadol 100 mg p.o 3 times daily for two days</description>
    <arm_group_label>tramadol 100 mg</arm_group_label>
    <other_name>group C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &lt;75 years old&#xD;
&#xD;
          -  patients discharged from Intensive Care Unit (ICU) in less than 30 hours&#xD;
&#xD;
          -  elective cardiac surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hepatic failure (increased transaminase levels&#xD;
&#xD;
          -  renal failure (creatinine&gt; 2 mg/dL)&#xD;
&#xD;
          -  ileus&#xD;
&#xD;
          -  emergency surgery (hemorrhage, tamponade, aortic dissection)&#xD;
&#xD;
          -  readmission in ICU&#xD;
&#xD;
          -  treatment with monoaminoxidase inhibitors, selective serotonine reuptake inhibitors or&#xD;
             antiepileptics&#xD;
&#xD;
          -  age&gt;75 years old&#xD;
&#xD;
          -  communication or language barriers&#xD;
&#xD;
          -  Lack of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kassiani Theodoraki, PhD, DESA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aretaieion University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kassiani Theodoraki, PhD, DESA</last_name>
    <phone>+306974634162</phone>
    <email>ktheodoraki@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Onassis Cardiac Surgery Centre</name>
      <address>
        <city>Athens</city>
        <zip>17674</zip>
        <country>Greece</country>
      </address>
    </facility>
    <contact>
      <last_name>Theophani Antoniou, MD, PhD</last_name>
      <email>antoniou_fani@yahoo.gr</email>
    </contact>
    <contact_backup>
      <last_name>Vassiliki Lavranou, MD</last_name>
      <email>vasolav82@hotmail.gr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Raksamani K, Wongkornrat W, Siriboon P, Pantisawat N. Pain management after cardiac surgery: are we underestimating post sternotomy pain? J Med Assoc Thai. 2013 Jul;96(7):824-8.</citation>
    <PMID>24319854</PMID>
  </reference>
  <reference>
    <citation>Roediger L, Larbuisson R, Lamy M. New approaches and old controversies to postoperative pain control following cardiac surgery. Eur J Anaesthesiol. 2006 Jul;23(7):539-50. Review.</citation>
    <PMID>16677435</PMID>
  </reference>
  <reference>
    <citation>Taillefer MC, Carrier M, Bélisle S, Levesque S, Lanctôt H, Boisvert AM, Choinière M. Prevalence, characteristics, and predictors of chronic nonanginal postoperative pain after a cardiac operation: a cross-sectional study. J Thorac Cardiovasc Surg. 2006 Jun;131(6):1274-80.</citation>
    <PMID>16733157</PMID>
  </reference>
  <reference>
    <citation>Gjeilo KH, Klepstad P, Wahba A, Lydersen S, Stenseth R. Chronic pain after cardiac surgery: a prospective study. Acta Anaesthesiol Scand. 2010 Jan;54(1):70-8. doi: 10.1111/j.1399-6576.2009.02097.x. Epub 2009 Aug 13.</citation>
    <PMID>19681771</PMID>
  </reference>
  <reference>
    <citation>Nachiyunde B, Lam L. The efficacy of different modes of analgesia in postoperative pain management and early mobilization in postoperative cardiac surgical patients: A systematic review. Ann Card Anaesth. 2018 Oct-Dec;21(4):363-370. doi: 10.4103/aca.ACA_186_17.</citation>
    <PMID>30333328</PMID>
  </reference>
  <reference>
    <citation>Tzschentke TM, Christoph T, Kögel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs. 2014 Apr;28(4):319-29. doi: 10.1007/s40263-014-0151-9. Review.</citation>
    <PMID>24578192</PMID>
  </reference>
  <reference>
    <citation>Langford RM, Knaggs R, Farquhar-Smith P, Dickenson AH. Is tapentadol different from classical opioids? A review of the evidence. Br J Pain. 2016 Nov;10(4):217-221. Epub 2016 Jul 25.</citation>
    <PMID>27867511</PMID>
  </reference>
  <reference>
    <citation>Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, Hertrampf T, Kögel B, Schiene K, Straßburger W, Terlinden R, Tzschentke TM. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012 Jul;13(10):1437-49. doi: 10.1517/14656566.2012.696097. Epub 2012 Jun 15. Review.</citation>
    <PMID>22698264</PMID>
  </reference>
  <reference>
    <citation>Lee YK, Ko JS, Rhim HY, Lee EJ, Karcher K, Li H, Shapiro D, Lee HS. Acute postoperative pain relief with immediate-release tapentadol: randomized, double-blind, placebo-controlled study conducted in South Korea. Curr Med Res Opin. 2014 Dec;30(12):2561-70. doi: 10.1185/03007995.2014.954665. Epub 2014 Aug 27.</citation>
    <PMID>25133962</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 17, 2021</study_first_submitted>
  <study_first_submitted_qc>January 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aretaieion University Hospital</investigator_affiliation>
    <investigator_full_name>Dr Kassiani Theodoraki</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>tapentadol</keyword>
  <keyword>tramadol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Pain, Procedural</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Tapentadol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

